Mapping the availability of RSV vaccine uptake data across Europe: a scoping review
File(s) ckag169.300.pdf (57.09 KB)
Abstract
OA Location
Author(s)
Type
Journal Article
Abstract
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Issue/Problem</jats:title>
<jats:p>Respiratory syncytial virus (RSV) is a leading cause of infant hospitalisation and morbidity across Europe, placing significant seasonal pressure on health services. New maternal and infant immunisation programmes have been implemented variably across countries. Programme effectiveness will depend on uptake of these strategies, and data are essential to enable evaluation, support shared learning, and ensure equitable access. We conducted a scoping review to map current RSV immunisation policies and the availability of uptake data across countries in Europe.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Description of the problem</jats:title>
<jats:p>We followed PRISMA-ScR guidelines and conducted a scoping review using PubMed, Google Scholar, and grey literature, including official government policy documents. Key search terms included “RSV”, “uptake”, “maternal vaccine”, “nirsevimab”, “coverage”, and “Europe”. Data were charted to address the following questions: (1) What immunisation strategy is used by each country as of April 2026 (maternal/infant/universal/at-risk)? (2) What is the availability of uptake data for these immunisation strategies? (3) At what level are these data reported (regional/national)?</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>Data were identified for 32 countries in Europe. Immunisation policies reported at the start of the 2025/2026 RSV season remained unchanged in April 2026, with most countries funding universal infant immunisation programmes. Uptake data was available for 16 countries (50%). Among these, 3/16 (19%) reported both nirsevimab and maternal vaccine uptake, 5/16 (31%) maternal vaccination only, and 7/16 (44%) nirsevimab only. Most data derive from regional studies, hospital cohorts or short-term evaluations rather than routine national surveillance data.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Lesson</jats:title>
<jats:p>Currently, data availability on uptake of new RSV immunisation strategies is low, limiting comparison of coverage and equity between countries and enabling shared learning on RSV immunisation implementation.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Key messages</jats:title>
<jats:p>• RSV maternal and infant immunisation uptake data availability varies across European countries.</jats:p>
<jats:p>• Increasing availability of uptake data would facilitate shared learning as countries implement these new immunisation strategies.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Issue/Problem</jats:title>
<jats:p>Respiratory syncytial virus (RSV) is a leading cause of infant hospitalisation and morbidity across Europe, placing significant seasonal pressure on health services. New maternal and infant immunisation programmes have been implemented variably across countries. Programme effectiveness will depend on uptake of these strategies, and data are essential to enable evaluation, support shared learning, and ensure equitable access. We conducted a scoping review to map current RSV immunisation policies and the availability of uptake data across countries in Europe.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Description of the problem</jats:title>
<jats:p>We followed PRISMA-ScR guidelines and conducted a scoping review using PubMed, Google Scholar, and grey literature, including official government policy documents. Key search terms included “RSV”, “uptake”, “maternal vaccine”, “nirsevimab”, “coverage”, and “Europe”. Data were charted to address the following questions: (1) What immunisation strategy is used by each country as of April 2026 (maternal/infant/universal/at-risk)? (2) What is the availability of uptake data for these immunisation strategies? (3) At what level are these data reported (regional/national)?</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>Data were identified for 32 countries in Europe. Immunisation policies reported at the start of the 2025/2026 RSV season remained unchanged in April 2026, with most countries funding universal infant immunisation programmes. Uptake data was available for 16 countries (50%). Among these, 3/16 (19%) reported both nirsevimab and maternal vaccine uptake, 5/16 (31%) maternal vaccination only, and 7/16 (44%) nirsevimab only. Most data derive from regional studies, hospital cohorts or short-term evaluations rather than routine national surveillance data.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Lesson</jats:title>
<jats:p>Currently, data availability on uptake of new RSV immunisation strategies is low, limiting comparison of coverage and equity between countries and enabling shared learning on RSV immunisation implementation.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Key messages</jats:title>
<jats:p>• RSV maternal and infant immunisation uptake data availability varies across European countries.</jats:p>
<jats:p>• Increasing availability of uptake data would facilitate shared learning as countries implement these new immunisation strategies.</jats:p>
</jats:sec>
Date Issued
2026-10-01
Date Acceptance
2026-10-01
Citation
European Journal of Public Health, 2026, 36 (Supplement_5)
ISSN
1101-1262
Publisher
Oxford University Press
Journal / Book Title
European Journal of Public Health
Volume
36
Issue
Supplement_5
Copyright Statement
© The Author(s) 2026. Published by Oxford University Press on behalf of the European Public Health Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
License URL
Publication Status
Published
Article Number
ckag169.300
Date Publish Online
2026-10-26
